Cerity Partners
HUMA icon

Cerity Partners’s Humacyte HUMA Stock Holding History

Cerity Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.4K Buy
51,821
+3,721
+8% +$3.45K ﹤0.01% 3317
2026
Q1 		$29.2K Buy
+48,100
New +$50K ﹤0.01% 3152
2025
Q3 		– Sell
-16,610
Closed -$34.7K – 2799
2025
Q2 		$34.7K Buy
+16,610
New +$31.9K ﹤0.01% 2576

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cerity Partners's HUMA Position: Q2 2026 in Review

Cerity Partners increased its Humacyte (HUMA) stake by 7.7% in Q2 2026, buying an estimated $3.45K and bringing the position to 51,821 shares worth $40.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3317.

Cerity Partners first reported a position in HUMA in Q2 2025 and has held it in 3 quarters since. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Cerity Partners held 51,821 shares of Humacyte worth $40.4K as of Q2 2026.
  • Cerity Partners bought 3,721 Humacyte shares in Q2 2026, an estimated $3.45K.
  • Humacyte made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3317 holding.
  • Cerity Partners first reported a position in Humacyte in Q2 2025 and has held it in 3 quarters since.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.